依折麦布联合瑞舒伐他汀治疗冠心病伴高胆固醇血症对患者血脂、CIMT及安全性的影响

Effects of Ezetimibe Combined with Rosuvastatin on Blood Lipid,CIMT and Safety in Patients with Coronary Heart Disease and Hypercholesterolemia

目的:探讨依折麦布联合瑞舒伐他汀治疗冠心病伴高胆固醇血症对患者血脂、颈动脉内膜中层厚度(CIMT)及安全性的影响。方法:选择2018年3月-2021年3月于沈阳二四五医院接受治疗的冠心病伴高胆固醇血症患者200例。按随机数字表法将患者分为单药组及联合组,各100例。单药组给予瑞舒伐他汀口服,联合组给予依折麦布联合瑞舒伐他汀口服。比较两组治疗前和治疗4、8周后低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)、甘油三酯(TG)、肌酸激酶(CK)、丙氨酸转氨酶(ALT)及天冬氨酸转氨酶(AST)。比较两组不良反应发生情况。比较两组治疗前及治疗6个月后CIMT。结果:治疗4、8周后,两组LDL-C、HDL-C、TC、TG均较治疗前改善,且联合组LDL-C、TC低于单药组,差异均有统计学意义(P<0.05);两组治疗4、8周后HDL-C、TG比较,差异均无统计学意义(P>0.05)。两组治疗前和治疗4、8周后CK、ALT、AST组间及组内比较,差异均无统计学意义(P>0.05)。两组均无严重不良反应发生,不良反应发生率比较,差异无统计学意义(P>0.05)。两组治疗前CIMT比较差异无统计学意义(P>0.05);治疗6个月后,两组CIMT均较治疗前降低,且联合组CIMT低于单药组(P<0.05)。结论:对于冠心病伴高胆固醇血症患者,依折麦布联合瑞舒伐他汀较单纯瑞舒伐他汀治疗更有利于降低血脂及颈动脉内膜中层厚度,安全有效。

Objective: To investigate the effects of Ezetimibe combined with Rosuvastatin on blood lipid, carotid intima media thickness(CIMT) and safety of coronary heart disease with hypercholesterolemia.Method: A total of 200 coronary heart disease patients with hypercholesterolemia who received treatment in Shenyang 245 Hospital from March 2018 to March 2021 were selected. According to random number table method,patients were divided into single drug group and combination group, 100 cases in each group. The single drug group was given Rosuvastatin orally, and the combination group was given Ezetimibe combined with Rosuvastatin orally. Low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C), total cholesterol(TC), triglyceride(TG), creatine kinase(CK), alanine aminotransferase(ALT) and aspartate aminotransferase(AST)were compared between the two groups before treatment and 4, 8 weeks after treatment. The incidence of adverse reactions was compared between the two groups. CIMT before treatment and 6 months after treatment were compared between the two groups. Result: After 4 and 8 weeks of treatment, LDL-C, HDL-C, TC and TG in two groups were improved compared with before treatment, and LDL-C and TC in combination group were lower than those in single drug group, the differences were statistically significant(P<0.05). There were no significant differences in HDL-C and TG between the two groups after 4 and 8 weeks of treatment(P>0.05). There were no significant differences in CK, ALT and AST between groups and within groups before treatment and 4 and 8 weeks after treatment(P>0.05).No serious adverse reactions occurred in two groups, and there was no statistical significance in the incidence of adverse reactions between two groups(P<0.05). There was no significant difference in CIMT between the two groups before treatment(P>0.05). After 6 months of treatment, CIMT in both groups were lower than those before treatment,and CIMT in combination group was lower than that in single drug group(P<0.05). Conclusion: For patients with coronary heart disease and hypercholesterolemia, Ezetimibe combined with Rosuvastatin is more beneficial to reduce blood lipid and carotid intima-media thickness than Rosuvastatin alone, which is safe and effective.